NDAVAGINALSUPPOSITORY
Approved
Aug 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
CLEOCIN (clindamycin phosphate) by Pfizer is clinical pharmacology mechanism of action clindamycin is an antibacterial drug (see). First approved in 1999.
Drug data last refreshed 7h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLEOCIN (clindamycin phosphate) is a vaginal suppository antibiotic indicated for bacterial vaginosis and other vaginal infections. It works by inhibiting bacterial protein synthesis, with local vaginal delivery achieving systemic absorption of approximately 30% with minimal systemic exposure compared to oral or parenteral routes.
$0.166MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D claims, indicating a mature/declining commercial footprint and likely smaller brand team.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Clindamycin is an antibacterial drug (See). Pharmacokinetics Systemic absorption of clindamycin was estimated following a once-a-day intravaginal dose of one clindamycin phosphate vaginal suppository (equivalent to 100 mg clindamycin) administered to 11…
Indications
Worked on CLEOCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.